SVRE vs CELU vs FATE vs AEYE vs CRSP

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate Fate Therapeutics, Inc. (FATE) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CRISPR Therapeutics AG (CRSP) delivered a total return of -46.

0%, compared to -100. 0% for SaverOne 2014 Ltd (SVRE). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus SVRE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SaverOne 2014 Ltd (SVRE) is the lower-risk stock at 1.

28β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 71% more volatile than SVRE relative to the S&P 500. On balance sheet safety, AudioEye, Inc. (AEYE) carries a lower debt/equity ratio of 15% versus 70% for SaverOne 2014 Ltd — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: SaverOne 2014 Ltd grew EPS 72. 2% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CELU (26.

2% yield) pays a dividend. SVRE, FATE, AEYE, CRSP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Celularity Inc.

(CELU) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (26. 2% yield). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CELU: -99. 1%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SVRE (Technology) and CELU (Healthcare) and FATE (Healthcare) and AEYE (Technology) and CRSP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SVRE is a small-cap quality compounder stock; CELU is a small-cap income-oriented stock; FATE is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock. CELU pays a dividend while SVRE, FATE, AEYE, CRSP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.